

TaiGen Biopharmaceuticals Holdings Limited

太景醫藥研發控股股份有限公司

Notification for the Annual General Meeting of Year 2026

2026 年股東常會開會通知書

- I. Date of Announcement : April 27, 2026
發文日期：2026 年 4 月 27 日
- II. Convener : The Board of Directors of TaiGen Biopharmaceuticals Holdings Limited
召集人：太景醫藥研發控股股份有限公司 董事會
- III. To : All shareholders
受文者：全體股東
- IV. Date of Annual Shareholders Meeting : 10:00 am., Wednesday, May 28, 2026
開會日期：2026 年 5 月 28 日(星期四)上午 10 時整
- V. Venue : B1., No. 28, Ln. 420, Sec. 5, Chenggong Rd., Neihu Dist., Taipei City , Taiwan (R.O.C.)
開會地點：台北市內湖區成功路五段 420 巷 28 號 B1
- VI. Attendees : Hsieh-Chang Li (CPA, Deloitte)
列席：勤業眾信會計師事務所 李協昌會計師
- VII. Share transfer recordation suspension period : From March 30, 2026 to May 28, 2026
股票停止過戶期間：2026 年 3 月 30 日至 2026 年 5 月 28 日
- VIII. Agenda 會議主要內容：
1. Report Items 報告事項
 - (1) 2025 Business Report.
2025 年度營業報告
 - (2) 2025 Audit Committee's Review Report to the Financial Statement.
審計委員會 2025 年度決算表冊之審查報告
 - (3) 2025 Report on the Distribution of Employees' Compensation and Directors' Remuneration
2025 年度員工酬勞及董事酬勞分派報告
 - (4) 2025 Directors' Remuneration
2025 年度董事酬金報告
 - (5) 2025 Report on the Implementation of Share Repurchase
本公司 2025 年度買回庫藏股執行情形報告
 - (6) Report on the Revision of the Company's ' Procedures for Ethical Management and

Guidelines for Conduct.

修訂本公司「誠信經營作業程序及行為指南」報告

2. Ratification Items 承認事項

- (1) To Ratify the 2025 Financial Statements and Business Report. (Ordinary Resolution)
2025年度財務報表暨營業報告書(普通決議)
- (2) To Ratify the surplus earnings distribution Proposal. (Ordinary Resolution)
2025年度盈餘分配案(普通決議)


3. Proposed Resolutions 討論事項

- (1) To revised the AMENDMENTS AND RESTATED RESTATED MEMORANDUM OF ASSOCIATION. (Special Resolution).
本公司「公司章程」部分條文修正案(特別決議)
- (2) Amendment to the Procedures for Acquisition and Disposal of Assets. (Ordinary Resolution)
本公司「取得或處分資產處理程序」部分條文修訂案，提請 議決。(普通決議)
- (3) Amendment to the Procedures for Lending Funds to Other Parties. (Ordinary Resolution)
本公司「資金貸與他人作業程序」部分條文修訂案，提請 議決。(普通決議)
- (4) Amendment to the Procedures for Endorsements and Guarantee. (Ordinary Resolution)
本公司「背書保證作業程序」部分條文修訂案，提請 議決。(普通決議)
- (5) Amendment to the Rules and Procedures for shareholders' Meetings (Ordinary Resolution)
本公司「股東會議事規則」部分條文修訂案，提請 議決。(普通決議)

4. Motions 臨時動議

5. Meeting adjourned 散會

By Order of the Board


Chairman 董事長：Philip Huang 黃國龍

Kindly schedule your time to attend the annual general meeting. If you are unable to attend and intend to give your proxy to another person, please sign or chop the proxy form and fill in the proxy's name and address, and then deliver the completed proxy form to the Company at least five days (no later than May 21, 2026) prior to the annual general meeting. Designated representative from the institutional investor has to bring the Power of Attorney signed and/or chopped when attending the annual general meeting.

至希 察照撥冗出席，如本人不克出席欲委託代理人出席，請於委託書上蓋章或簽名，並填妥代理人姓名、地址後於開會五日前(至遲於 2026 年 5 月 21 日)送(寄)達本公司。法人股東指派代表人出席時請出具簽名或用印之指派書。

Contact person 聯絡人： Tel: 886-2-8177-7020 Ext # 1716 吳先生 (Andy Wu)
Email: andywu@taigenbiotech.com